key: cord-0798266-1ki4ukdp
authors: Prasad, Manya; Seth, Tulika; Elavarasi, Arunmozhimaran
title: Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis
date: 2021-03-16
journal: Indian J Hematol Blood Transfus
DOI: 10.1007/s12288-021-01417-w
sha: ec383553734652dffb9874e76319aaac57270b5c
doc_id: 798266
cord_uid: 1ki4ukdp

Convalescent plasma is currently being used in the treatment of COVID-19. Recommendations regarding use convalescent plasma in COVID-19 requires systematic summaries of available evidence. We searched the databases Medline, Embase, Cochrane CENTRAL, Epistomonikos, Medrxiv and Biorxiv. Title/abstract screening, full text screening and data abstraction were carried out in duplicate by two reviewers. Pooled effect sizes and 95% confidence intervals were calculated using random effects meta-analysis. GRADE tool was used to rate the certainty of evidence. Twenty two studies were found eligible for inclusion: nine randomized controlled trials and thirteen cohort studies. Low certainty evidence from eight RCTs showed inconclusive effects of convalescent plasma on mortality at 28 days (OR 0.85, 95% CI 0.61 to 1.18). Low certainty evidence from thirteen cohort studies showed a reduction in mortality at 28 days (OR 0.66, 95% CI 0.53 to 0.82). The pooled OR for clinical improvement was 1.07 (95% CI 0.86 to 1.34) representing low certainty evidence. Evidence from three RCTs showed inconclusive effect of CP on the need for mechanical ventilation (OR 1.20, 95% CI 0.72 to 1.98). Four cohort studies reporting unadjusted estimates suggested a reduction in the need for mechanical ventilation with convalescent plasma (OR 0.80 95% CI 0.71 to 0.91, low certainty). Pooled estimates from 2 RCTs showed inconclusive effects of convalescent plasma on the proportion of patients with nondetectable levels of virus in nasopharyngeal specimens on day 3 (OR 3.62, 95% CI 0.43, 30.49, very low-quality evidence). The present review reports uncertain estimates on the efficacy of convalescent plasma in the treatment of COVID-19. There is low certainty evidence of a possible reduction in mortality and mechanical ventilation, a faster viral clearance and the absence of any serious adverse events. However, its efficacy for these outcomes requires evidence from good quality and adequately powered randomized controlled trials. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12288-021-01417-w.

The worldwide spread of COVID-19, the illness caused by SARS-CoV-2, poses an enormous threat to human health, and is a cause of major social and economic crises worldwide. As of January 2021, COVID-19 has resulted in more than 2 million deaths worldwide (1), and its transmission continues unabated in many parts of the globe.

The massive potential for adverse health consequences from this pandemic has led to a desperate need for interventions that can reduce the resulting morbidity and Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s12288-021-01417-w. mortality. Research is ongoing to develop vaccines and identify therapeutics for COVID-19, including repurposing of medications [2] . A globally implemented, safe mass vaccination programme seems to be the only long term solution; [3] . Interventions with evidence of reducing morbidity and mortality from this disease are urgently required in order to form the bridge to the endgame of mass vaccination.

However, the use of medications without proven effectiveness may result in avoidable harm to patients, detract investment in other resources and erode public trust in the medical community [4, 5] .

Convalescent plasma (CP) is currently being used in the treatment of COVID-19 with the rationale that it contains antibodies that potentially neutralize the virus and thus prevent the inflammatory cascade that ensues. It has been used historically for the treatment of infectious diseases and there is also some evidence of its usefulness in the treatment of other coronavirus infections like SARS and MERS [6, 7] .

Recommendation regarding use convalescent plasma in COVID-19 requires systematic summaries of available evidence. At a time when research is being produced at an unprecedented pace, it is necessary to rigorously appraise the evidence to distinguish the trustworthy from the untrustworthy. Moreover, in the context of COVID-19, where the best evidence is constantly changing, it is required that we have the most updated summaries available for practice. Therefore, we conducted a systematic review and meta-analysis to study the efficacy and safety of convalescent plasma in patients with COVID-19.

The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-analysis of observational studies in epidemiology (MOOSE) statements were adhered to in the present report [8, 9] . We developed a protocol before beginning this systematic review. The protocol for this review was registered in PROSPERO, with the registration number CRD42020227417.

The following inclusion criteria were used for eligibility:

Type of participants We included studies on patients with severe and non-severe COVID- 19 .

Type of intervention We included studies assessing intravenous convalescent or hyperimmune plasma as an intervention in addition to standard of care Type of outcomes We included studies reporting the following outcomes:

Primary outcome: Overall mortality Secondary outcomes:

• Clinical recovery • Rate of ICU admission • Length of ICU stay • Length of hospital stay • Need for mechanical ventilation • Viral clearance • Adverse events: Intravascular volume overload related complications and transfusion-related acute lung injury, allergy or anaphylaxis, and any other patient-important safety outcomes that study reports

Type of Studies We included randomized controlled trials, cohort studies and case series that compared the use of convalescent plasma to treatment without convalescent plasma and reported on at least one of our outcomes of interest. We excluded case series in which all patients, or no patients, received convalescent plasma.

We searched in the following databases: Medline (Ovid), Embase, Cochrane CENTRAL, Epistomonikos and ran a PubMed search for studies not yet indexed in Medline. We reviewed reference lists of all included studies and relevant systematic reviews for additional references. We searched medRxiv and biorxiv for any relevant pre-print previews.

No language restriction was imposed. The search strategy implemented is provided in Appendix 1. The search was updated till 15 th January 2021.

Pairs of reviewers independently screened titles and abstracts, and reviewed the full texts of potential eligible studies to determine the final eligible studies. Disagreements were resolved by discussion or by referring to a third reviewer.

Pairs of reviewers abstracted data. We abstracted surname of the first author, year of publication, country, region and hospital, population, interventions, and outcomes. For cohort studies, we also abstracted the method of adjustment used and covariates adjusted for in the analysis. Disagreements were resolved by discussion or, if necessary, by a third reviewer.

We assessed the risk of bias in randomized trials using the modified Cochrane tool that includes sequence generation, allocation sequence concealment, blinding, and missing outcome data. Each criterion was judged as definitely or probably low risk of bias, or probably or definitely high risk of bias [8] . We assessed risk of bias in cohort studies using the New Castle Ottawa scale for Cohort studies [9] . Two review authors independently assessed the study risk of bias with disagreements resolved by involving a third reviewer.

We calculated pooled odds ratio (OR) and 95% confidence intervals (95% CI) for dichotomous outcomes. We used adjusted estimates from studies wherever reported, and used the random-effects models to pool study data. We used DerSimonian and Laird inverse variance random-effect models to pool adjusted odds ratios (ORs). We carried out all statistical analyses using Review Manager 5.3. We assessed heterogeneity in the meta-analyses by visual inspection of the forest plot and by the I 2 statistic.

We used the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology to rate the certainty in evidence for each outcome as high, moderate, low, or very low [10] . The assessment included judgments addressing risk of bias, imprecision, inconsistency, indirectness, and publication bias.

We summarized the evidence both narratively and in GRADE evidence profiles.

Our search yielded 3993 titles and abstracts -all were identified from the electronic database search. We excluded 3935 articles based on a review of the title and abstract, leaving 58 articles for full review. Of these, 36 were excluded-33 for having an inappropriate study design, two for having inappropriate comparison, one for including a duplicate population. Twenty two studies were found eligible on full text screening. Nine of these were pre-print articles that had not been peer reviewed [12-16, 20, 24, 28, 32] . These 22 studies were included in the systematic review and meta-analyses. (Fig. 1) .

The studies included were nine randomized controlled trials (1254 patients) [11] [12] [13] [14] [15] [16] [26] [27] [28] and thirteen cohort studies (8368 patients) [16] [17] [18] [19] [20] [21] [22] [23] [24] [29] [30] [31] [32] . All studies included patients hospitalized with COVID-19 (Tables 1 and 2) . Most studies included patients with severe COVID-19 except one study that included moderately ill patients [12] .

All trials were assessed to have low risk of bias for adequate random sequence generation and allocation concealment. Risk of bias for selective outcome reporting and missing outcome data was assessed to be low as most studies reported important outcomes and very less loss to follow up. However, only two trials were blinded and four were stopped early [11, 13, 14, 27] . Three trials reported stopping early because the epidemic had considerably diminished and the trial saw low enrolment [11, 14, 27] ; while one reported stopping early since a high proportion of patients were found to have SARS-CoV-2 antibodies at baseline [13] . All trials were also assessed to be high risk of bias due to imbalance of co-interventions amongst the two arms.

For all outcomes in the cohort studies, risk of bias was low for selection of exposed and non-exposed population and assessment of exposure. All cohort studies were assessed to have low risk of bias from outcome being present at the start of the study. However, adequate adjustment and assessment of prognostic factors were not carried out by three studies. Follow up was adequate for all outcomes in the cohort studies; however, no study documented similar co-interventions in both groups (Tables 3  and 4 ).

Low certainty evidence from 8 RCTs (n = 1374) (11) (12) (13) (14) (15) (26) (27) (28) showed inconclusive effects of convalescent plasma on mortality at 28 days with a possible but uncertain reduction in mortality (OR 0.85, 95% CI 0.61 to 1.18, I 2 =0%) ( Fig. 2 and Table 5 ).

Low certainty evidence from 13 cohort studies [17] [18] [19] [20] [21] [22] [23] [24] [25] [29] [30] [31] [32] (n=8368) showed a reduction in mortality at 28 days (OR 0.66, 95% CI 0.53 to 0.82, I 2 =26%). (Fig. 3 and Table 5 ).

Two RCTs reported ordinal outcomes relating to extent of clinical improvement at 30 days and one RCT at 14 days. The pooled OR for clinical improvement (522 patients) [11, 13, 26] was OR 1.07 (95% CI 0.86 to 1.34) representing low certainty evidence ( Fig. 4 and Table 5 ).

Evidence from 3 RCTs and one cohort study [12, 15, 25, 26] suggested uncertain effect of convalescent plasma on decreasing length of hospital stay (MD 0.12, 95% CI -1.69 to 1.93) ( Fig. 5 and Table 5 ).

Evidence from three RCTs (n=522) [12, 16, 26] showed inconclusive effect of CP on need for mechanical ventilation (OR 1.20, 95% CI 0.72 to 1.98, I 2 =0%, low certainty).

However, four cohort studies reporting unadjusted estimates suggested a reduction in the need for mechanical ventilation with convalescent plasma (OR 0.80 95% CI 0.71 to 0.91, I 2 =0%, low certainty) ( Fig. 6 and Table 5 ).

One RCT (n=522) [12] showed higher proportion of patients with undetectable virus on day 7 (OR 1.52, 95% CI 1.06, 2.20).

Pooled estimates from 2 RCTs (n = 609) [11, 12] showed inconclusive effects of convalescent plasma on the proportion of patients with nondetectable levels of virus in nasopharyngeal specimens on day 3 (OR 3.62, 95% CI 0.43, 30.49, very low-quality evidence) ( Fig. 7 and Table 5 ).

There were very few adverse events reported in all included studies, with most trials and cohort studies not reporting any adverse events. 

The results of our meta-analysis show that there is very low to low certainty evidence to suggest that CP does not reduce mortality, hospital stay, need for mechanical ventilation or improvement in clinical status. Based on a single study, whether CP improves viral clearance is not clear. The theory behind using CP for treatment goes back to the early days of antimicrobial therapy when it was used for pneumococcal pneumonia [6] . More recently, it has been used in the treatment for various viral diseases like SARS, MERS and Ebola [7] . The rationale is that antibodies in CP have the capacity to work in two different ways: first is the potential to act on the microbes causing the infection, and the second is that they can exert immunomodulatory therapy, thus boosting the immunity of the patient.

The included studies demonstrated a very good safety profile for CP. There is a theoretical possibility of antibody dependent enhancement [33] , though there are no reports of this from trials.

However, the use of convalescent plasma as therapy for COVID-19 is not without challenges. Only limited quantities of plasma can be obtained at a time and its collection consumes resources. There is considerable difference in the titres, antibody response and type of antibodies amongst people. Besides this, though most studies did not report many adverse events, there are safety issues related to transfusion such as acute lung injury, transfusion related circulatory overload and anaphylaxis that need to be managed at times [34] . Risk of transmission of blood borne infections is also a potential threat to recipients of CP.

In March 2020, the US FDA approved convalescent plasma as an investigational new drug in the expanded access program. The unadjusted analysis of data from the EAP, though not comparing CP with no CP, suggested that treatment given early after diagnosis (within 3 days) is associated with lower 7-day and 30-day mortality, and transfusion of convalescent plasma with high SARS-CoV-2 IgG antibody levels compared to medium or low IgG levels was furthermore associated with lower mortality. This could be an explanation as to why other studies investigating convalescent plasma may not be able to detect a clinically relevant difference, although these findings should be confirmed in RCTs before it can be translated into practice [35] .

To the best of our knowledge, there is no previous systematic review that has included all the studies included in the present review. Some previous systematic reviews and meta-analyses have evaluated the efficacy of CP in the treatment of COVID-19. Chai et al in a Cochrane review that included two trials and eight NRSIs, concluded that [38] . The review by Devasenapathy et al provided indirect evidence of the role of CP from studies on SARS, MERS, Influenza and Ebola. However, they reported very low-quality evidence that raised the possibility that CP has minimal or no benefit in the treatment of COVID-19 and low-quality evidence that it does not cause serious adverse events [7] .

The present systematic review incorporates a robust search strategy with a comprehensive search of three major databases as well as preprint servers. Screening of titles, abstracts and full texts was done independently by two reviews in duplicate, as was the data abstraction including risk of bias assessments. Lastly, we used the GRADE methodology to rate the certainty in the evidence, thus enabling us to pay close attention to methodological issues like inconsistency, imprecision and risk of bias.

The limitations of the present review are largely due to the limitations of the included primary studies, most of which yielded imprecise estimates. Imprecision persisted for most outcomes in the meta-analyses since evidence from large RCTs are not yet available. Though we used the adjusted estimates wherever reported, many studies failed to report adjusted estimates and were assessed as having serious risk of bias due to confounding. Another consideration is that this review includes evidence from pre-print articles, the quality of which has not been peer-reviewed and the results of which are subject to change following the peer review process. The number of included studies were few, precluding the possibility of subgroup analyses to explore the heterogeneity observed in the meta-analyses of some outcomes. However, the difference in severity of patients included amongst trials could possibly explain the heterogeneity. For instance, Agarwal et al [12] enrolled There is limited knowledge so far with regard to what level of antibody titre is protective and three of the included studies did not measure antibody titres of donors [19, 21, 25] . There is very limited reporting of adverse Uncertainty remains regarding the role of convalescent plasma in the treatment of COVID-19. There is low certainty evidence of a possible reduction in mortality and mechanical ventilation, a faster viral clearance and the absence of any serious adverse events. However, its 

Johns Hopkins coronavirus resource center

Pharmacologic treatments for coronavirus disease 2019 COVID-19. A review

Developing a SARS-CoV-2 vaccine at warp speed

Finding effective treatments for COVID-19: scientific integrity and public confidence in a time of crisis

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

Convalescent plasma therapy for COVID-19: a triedand-true old strategy?

Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis

Modification of cochrane tool to assess risk of bias in randomized trials

Tool to assess risk of bias in cohort studies

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

Effect of convalescent plasma therapy on time to clinical Fig. 6 Effect of convalescent plasma on need for mechanical ventilation Fig

Blood Transfus improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial)

Convalescent plasma for COVID-19 A randomized clinical trial

Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial

Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients A Pilot Randomized Controlled Trial. medRxiv

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: a preliminary report

Convalescent plasma for patients with severe COVID-19: a matched cohort study

Treatment of COVID-19 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality. The American journal of pathology

Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion

Convalescent plasma treatment of severe COVID-19 a propensity score-matched control study

Effect of convalescent plasma on mortality in patients with Covid-19 pneumonia

Convalescent plasma therapy in patients with COVID-19

A randomized trial of convalescent plasma in Covid-19 severe pneumonia

Early High-titer plasma therapy to prevent severe Covid-19 in older adults

Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial

Use of convalescent plasma in hospitalized patients with COVID-19: case series

Clinical efficacy of convalescent plasma therapy on treating COVID-19 patients: Evidence from matched study and a meta-analysis

COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: a multicenter interventional study

Treatment of severe COVID-19 with convalescent plasma in the Bronx NYC

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial Threemonth experience

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review

Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: a systematic review and meta-analysis

Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations